These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8070502)

  • 1. Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size.
    Zambon S; Cortella A; Sartore G; Baldo-Enzi G; Manzato E; Crepaldi G
    Eur J Clin Pharmacol; 1994; 46(3):221-4. PubMed ID: 8070502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia.
    Contacos C; Barter PJ; Sullivan DR
    Arterioscler Thromb; 1993 Dec; 13(12):1755-62. PubMed ID: 8241095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome.
    Toto RD; Grundy SM; Vega GL
    Am J Nephrol; 2000; 20(1):12-7. PubMed ID: 10644862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
    Sirtori CR; Calabresi L; Pisciotta L; Cattin L; Pauciullo P; Montagnani M; Manzato E; Bittolo Bon G; Fellin R
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):47-55. PubMed ID: 15871851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin.
    Lijnen P; Celis H; Desager JP; Fagard R
    J Hum Hypertens; 1995 Jul; 9(7):557-64. PubMed ID: 7562885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
    Boquist S; Karpe F; Danell-Toverud K; Hamsten A
    Atherosclerosis; 2002 May; 162(1):163-70. PubMed ID: 11947910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern.
    Franceschini G; Cassinotti M; Vecchio G; Gianfranceschi G; Pazzucconi F; Murakami T; Sirtori M; D'Acquarica AL; Sirtori CR
    Arterioscler Thromb; 1994 Oct; 14(10):1569-75. PubMed ID: 7918306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
    Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a reduced-fat diet with or without pravastatin on glucose tolerance and insulin sensitivity in patients with primary hypercholesterolemia.
    Galvan AQ; Natali A; Baldi S; Frascerra S; Sampietro T; Galetta F; Seghieri G; Ferrannini E
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):595-602. PubMed ID: 8891888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate.
    Masana L; Villoria J; Sust M; Ros E; Plana N; Pérez-Jiménez F; Franco M; Oliván JJ; Pintó X; Videla S
    Eur J Pharmacol; 2004 Aug; 496(1-3):205-12. PubMed ID: 15288592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin.
    Contacos C; Barter PJ; Vrga L; Sullivan DR
    Atherosclerosis; 1998 Nov; 141(1):87-98. PubMed ID: 9863541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.
    Lee SJ; Sacks FM
    Am J Cardiol; 2003 Jul; 92(2):121-4. PubMed ID: 12860210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses.
    Calabresi L; Donati D; Pazzucconi F; Sirtori CR; Franceschini G
    Atherosclerosis; 2000 Feb; 148(2):387-96. PubMed ID: 10657575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of pravastatin in hypertensive hypercholesterolaemic patients on antihypertensive drug therapy.
    Celis H; Lijnen P; Fagard R; Staessen J; Thijs L; Amery A
    J Hum Hypertens; 1994 Jul; 8(7):525-30. PubMed ID: 7932517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with probucol and pravastatin in hypercholesterolaemia. One year follow-up study.
    Saku K; Zhang B; Hirata K; Okura Y; Bai H; Liu R; Arakawa K
    Eur J Clin Pharmacol; 1993; 44(6):535-9. PubMed ID: 8405008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.
    Wiklund O; Angelin B; Bergman M; Berglund L; Bondjers G; Carlsson A; Lindén T; Miettinen T; Odman B; Olofsson SO
    Am J Med; 1993 Jan; 94(1):13-20. PubMed ID: 8420296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
    Lemieux I; Laperrière L; Dzavik V; Tremblay G; Bourgeois J; Després JP
    Atherosclerosis; 2002 Jun; 162(2):363-71. PubMed ID: 11996956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P; Echevaría-Vázquez D; Petrov V
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.